The major difference is that Prkar2a+/− and Prkar2a−/− mice develop with a high frequency hematopoietic neoplasms, particularly macrophage-derived HS tumors, as well as neoplasms derived from mature cells of the B cell lineage. This evidence concerns the gene PRKAR2A and histiocytic sarcoma.